Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cannabidiol/tetrahydrocannabivarin-9

Next Previous
X
Search
Drug Profile

Cannabidiol/tetrahydrocannabivarin-9

Alternative Names: Cannabidiol/delta-9-tetrahydrocannabivarin - GW Pharmaceuticals; GW42004/GW42003; Tetrahydrocannabivarol-9/cannabidiol; THCV/CBD

Latest Information Update: 07 May 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GW Pharmaceuticals
  • Class Antihyperglycaemics; Antihyperlipidaemics; Cannabinoids
  • Mechanism of Action Cannabinoid receptor CB1 antagonists; Cannabinoid receptor CB2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Dyslipidaemias; Metabolic disorders

Highest Development Phases

  • Discontinued Dyslipidaemias; Metabolic syndrome; Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 05 May 2021 GW Pharmaceuticals has been acquired by Jazz Pharmaceuticals plc
  • 01 Jun 2018 Chemical structure information added
  • 06 Apr 2018 Discontinued - Phase-II for Dyslipidaemias in United Kingdom (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top